Registered title, quoted from ClinicalTrials.gov
Local Consolidative Therapy Versus Maintenance Immunotherapy After First-Line Chemoimmunotherapy in Metastatic NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Guangdong Provincial People's Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07842471, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically/cytologically confirmed non-small cell lung cancer (NSCLC) at initial diagnosis, with TNM stage IV (IASLC 9th edition);
Inclusion criterion 5
Diagnosis of another malignancy within 3 years prior to signing informed consent, excluding cured cases of cutaneous basal cell carcinoma, cervical or breast in situ carcinoma, superficial bladder cancer, localized prostate cancer; participants with low-risk early-stage prostate cancer (T1-T2a stage, Gleason score ≤6, PSA <10 ng/mL) are eligible if they have undergone curative treatment or are under active surveillance with stable disease, regardless of whether they have received treatment;
Exclusion criterion 13
Pregnant, breastfeeding, or planning pregnancy; positive pregnancy test within 7 days prior to first study treatment;
Exclusion criterion 15
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
Inclusion criterion 3
Absence of actionable genetic mutations related to EGFR/ALK/ROS1 and other druggable targets;
Inclusion criterion 6
Achievement of partial response (PR) or complete response (CR) as assessed by RECIST 1.1 criteria;
Inclusion criterion 8
Presence of metabolically active residual lesions on PET evaluation, and clinical assessment by the multidisciplinary team (MDT)* indicating feasibility of individualized local therapy (e.g., ≤3 organs and ≤5 lesions, amenable to surgery/radiotherapy/ablation);
Inclusion criterion 9
Positive serum test for human immunodeficiency virus (HIV);
Exclusion criterion 8
Active hepatitis B: positive hepatitis B surface antigen (HBsAg) and HBV-DNA quantitative test >500 IU/mL or >2000 copies/mL;
Exclusion criterion 9
Active hepatitis C: positive hepatitis C virus (HCV) antibody and HCV-RNA quantitative test above the upper limit of normal;
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07842471, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation in the study with signed informed consent;
- Age ≥18 years, both male and female;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
- Estimated life expectancy ≥12 months;
- Histologically/cytologically confirmed non-small cell lung cancer (NSCLC) at initial diagnosis, with TNM stage IV (IASLC 9th edition);
- Absence of actionable genetic mutations related to EGFR/ALK/ROS1 and other druggable targets;
- Completion of 4-6 cycles of immunotherapy (PD-1/PD-L1 monoclonal antibody) combined with platinum-based doublet chemotherapy prior to enrollment;
- Achievement of partial response (PR) or complete response (CR) as assessed by RECIST 1.1 criteria;
- Presence of metabolically active residual lesions on PET evaluation, and clinical assessment by the multidisciplinary team (MDT)* indicating feasibility of individualized local therapy (e.g., ≤3 organs and ≤5 lesions, amenable to surgery/radiotherapy/ablation);
- Adequate organ function.
Exclusion Criteria:
- Expected to be unable to tolerate surgery, radiation therapy, or ablation;
- Unable to receive local treatment for all active residual lesions;
- Patients with a confirmed history of malignant pleural effusion or pleural dissemination;
- Pathologically diagnosed with neuroendocrine cancer at initial diagnosis (including small cell lung cancer, combined small cell lung cancer, large cell neuroendocrine carcinoma, mixed large cell neuroendocrine carcinoma, and carcinoid). Patients who do not show neuroendocrine components at initial diagnosis but develop such components in post-surgical pathology may be included;
- Previously received allogeneic tissue or solid organ transplantation;
- History of interstitial lung disease requiring steroid treatment (non-infectious) or currently suffering from interstitial lung disease requiring steroid treatment;
- Presence of viral infectious diseases during screening:
- Positive serum test for human immunodeficiency virus (HIV);
- Active hepatitis B: positive hepatitis B surface antigen (HBsAg) and HBV-DNA quantitative test >500 IU/mL or >2000 copies/mL;
- Active hepatitis C: positive hepatitis C virus (HCV) antibody and HCV-RNA quantitative test above the upper limit of normal;
- Participants with uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg (adjustment of antihypertensive medications is allowed prior to study initiation, but the average of the most recent three consecutive blood pressure readings before enrollment must be ≤150/90 mmHg) (each measurement separated by at least 2 minutes);
- Active infection requiring intravenous antimicrobial therapy at screening;
- Diagnosis of another malignancy within 3 years prior to signing informed consent, excluding cured cases of cutaneous basal cell carcinoma, cervical or breast in situ carcinoma, superficial bladder cancer, localized prostate cancer; participants with low-risk early-stage prostate cancer (T1-T2a stage, Gleason score ≤6, PSA <10 ng/mL) are eligible if they have undergone curative treatment or are under active surveillance with stable disease, regardless of whether they have received treatment;
- Conditions that may interfere with interpretation of study results or affect the participant's ability to complete the entire study, or where, in the investigator's judgment, participation does not serve the participant's best interest;
- Pregnant, breastfeeding, or planning pregnancy; positive pregnancy test within 7 days prior to first study treatment;
- Poor compliance, unwillingness or inability to follow the study procedures as required.
Quoted from ClinicalTrials.gov, NCT07842471, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07842471, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.